Copyright
©The Author(s) 2021.
World J Clin Cases. Oct 6, 2021; 9(28): 8349-8357
Published online Oct 6, 2021. doi: 10.12998/wjcc.v9.i28.8349
Published online Oct 6, 2021. doi: 10.12998/wjcc.v9.i28.8349
Group | FSH (IU/L) | E2 (pg/mL) | AMH (ng/mL) | |||
Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | |
Fenmatong group | 18.21 ± 2.44 | 13.78 ± 2.06 | 25.38 ± 3.24 | 44.23 ± 4.05 | 0.22 ± 0.05 | 0.26 ± 0.07 |
Observation group | 18.14 ± 2.26 | 10.14 ± 1.57 | 24.89 ± 4.77 | 57.96 ± 5.17 | 0.21 ± 0.08 | 0.29 ± 0.09 |
t | 0.170 | 11.330 | 0.685 | 16.855 | 0.855 | 2.121 |
P value | 0.866 | 0.000 | 0.495 | 0.000 | 0.394 | 0.036 |
- Citation: Lin XM, Chen M, Wang QL, Ye XM, Chen HF. Clinical observation of Kuntai capsule combined with Fenmotong in treatment of decline of ovarian reserve function. World J Clin Cases 2021; 9(28): 8349-8357
- URL: https://www.wjgnet.com/2307-8960/full/v9/i28/8349.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i28.8349